LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Inicio・Lista de Acciones・Xencor Inc

Xencor Inc

Cerrado

SectorSanidad

11.24 -5.15

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

10.92

Máximo

11.82

Métricas clave
By Trading Economics
Ingresos	-214M -129M
Ventas	-24M 4.5M
BPA	-1.71
Margen de beneficios	-2,854.65
Empleados	260
EBITDA	-81M -75M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+110.02% upside

Dividendos
By Dow Jones
Próximas Ganancias	4 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-42M 948M
Apertura anterior	16.39
Cierre anterior	11.24

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

96 / 346 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

7.87 / 10.84 Soporte y Resistencia

Xencor Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

14 may 2026, 22:44 UTC

Adquisiciones, fusiones, absorciones

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14 may 2026, 22:27 UTC

Adquisiciones, fusiones, absorciones

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14 may 2026, 22:12 UTC

Ganancias

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14 may 2026, 21:52 UTC

Adquisiciones, fusiones, absorciones

LVMH to Sell Marc Jacobs

15 may 2026, 00:00 UTC

Ganancias

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14 may 2026, 23:57 UTC

Adquisiciones, fusiones, absorciones

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14 may 2026, 23:56 UTC

Adquisiciones, fusiones, absorciones

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14 may 2026, 23:56 UTC

Adquisiciones, fusiones, absorciones

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14 may 2026, 23:56 UTC

Charlas de Mercado

Gold Prices Rise on Strong Demand -- Market Talk

14 may 2026, 23:56 UTC

Adquisiciones, fusiones, absorciones

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14 may 2026, 23:50 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

14 may 2026, 23:50 UTC

Charlas de Mercado

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14 may 2026, 23:47 UTC

Ganancias

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14 may 2026, 23:47 UTC

Ganancias

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14 may 2026, 23:46 UTC

Ganancias

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14 may 2026, 23:46 UTC

Ganancias

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14 may 2026, 23:28 UTC

Charlas de Mercado

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14 may 2026, 23:00 UTC

Charlas de Mercado

Australia's One Nation Party Leads In The Polls -- Market Talk

14 may 2026, 22:46 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

14 may 2026, 22:46 UTC

Charlas de Mercado

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14 may 2026, 22:46 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

14 may 2026, 22:35 UTC

Charlas de Mercado

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14 may 2026, 22:11 UTC

Adquisiciones, fusiones, absorciones

LVMH Agrees to Sell Marc Jacobs -- WSJ

14 may 2026, 22:06 UTC

Charlas de Mercado

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14 may 2026, 22:04 UTC

Ganancias

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14 may 2026, 22:04 UTC

Ganancias

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14 may 2026, 22:04 UTC

Ganancias

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14 may 2026, 22:00 UTC

Ganancias

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14 may 2026, 21:55 UTC

Ganancias

Nu Holdings 1Q EPS 18c >NU

14 may 2026, 21:55 UTC

Ganancias

Nu Holdings 1Q Rev $4.97B >NU

Comparación entre iguales

Cambio de precio

Xencor Inc previsión

Precio Objetivo

By TipRanks

110.02% repunte

Estimación a 12 Meses

Media 26 USD 110.02%

Máximo 43 USD

Mínimo 13 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Xencor Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

12 ratings

Comprar

Mantener

Vender

De acuerdo con 12 analistas que ofrecen calificaciones bursátiles a para Xencor Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

7.87 / 10.84Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bearish.

Sentimiento

By Acuity

96 / 346 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.